Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENSKYCE vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Induction and maintenance of sedation in adult patients undergoing diagnostic or therapeutic procedures
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
12 hours (terminal); allows once-daily dosing in most patients
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Fospropofol is rapidly converted to propofol, phosphate, and formaldehyde by alkaline phosphatases (primarily in liver and plasma). Propofol is then metabolized in the liver via glucuronidation (UGT1A9) and hydroxylation (CYP2B6, CYP2C9) to inactive metabolites.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
95% bound to albumin
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
0.25 L/kg (low, indicates minimal tissue distribution)
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: 80% (with interindividual variability)
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
Cr Cl 30-79 m L/min: No adjustment. Cr Cl 15-29 m L/min: Reduce dose to 1 g IV every 8 hours. Cr Cl <15 m L/min: Use 1 g IV every 24 hours; consider alternative therapy.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 1.5 g IV every 8 hours. Child-Pugh C: Use 1 g IV every 12 hours; clinical monitoring recommended.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not approved for use in pediatric patients; safety and efficacy not established.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
No specific dose adjustment required; monitor renal function and adjust based on creatinine clearance.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
WARNING: RISK OF RESPIRATORY DEPRESSION AND NEED FOR RESUSCITATION EQUIPMENT. ENSKYCE should be administered only by personnel trained in the administration of general anesthesia and management of airway emergencies. Resuscitation equipment and drugs must be immediately available. Because of the potential for respiratory depression, patients must be continuously monitored for respiratory function.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Respiratory depression and apnea,Hypotension and bradycardia,Must only be administered by trained anesthesia personnel,Risk of propofol infusion syndrome (with prolonged use),May cause hypotension; correct hypovolemia before administration,Use caution in elderly or debilitated patients,May cause pain on injection,Monitoring of vital signs required
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Hypersensitivity to propofol or any component of the formulation,Hypersensitivity to eggs, soy products, or peanuts (due to excipients),Patients with severe hepatic impairment or lipid metabolism disorders (relative)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
Avoid high-fat, fried, or spicy foods as they may exacerbate gastrointestinal adverse effects; take with or without food; maintain adequate fluid intake to reduce constipation risk; no specific food-drug interactions but alcohol may increase hypoglycemic risk when combined with other antidiabetic drugs.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
No human data available; animal studies show no teratogenic effects at clinically relevant doses. Risk cannot be excluded in first trimester; avoid use unless benefit outweighs risk. Second and third trimester: no known fetal risks, but limited data.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
No data on secretion in human milk; M/P ratio unknown. Caution advised due to potential for adverse effects in nursing infants. Weigh benefits against risks.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
No established dose adjustments for pregnancy. Pharmacokinetic changes (increased volume of distribution, enhanced clearance) may reduce drug exposure; monitor clinical response and consider dose titration if efficacy wanes.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
Start with 2.5 mg once weekly, escalate by 2.5 mg increments every 4 weeks to minimize gastrointestinal intolerance; monitor renal function (e GFR required before initiation); if e GFR <30 m L/min/1.73 m², use 0.5 mg initiation and titrate slowly; switch from subcutaneous semaglutide to ENSKYCE requires same dose but monitor for 4 weeks for GI side effects; thyroid C-cell tumor risk requires baseline calcitonin; do not use in patients with personal or family history of medullary thyroid carcinoma or MEN2.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take exactly as prescribed; do not change dose or frequency without consulting doctor.,Visual injection aids: inject subcutaneously in abdomen, thigh, or upper arm, rotating sites weekly.,Most common side effects are nausea, vomiting, diarrhea, and constipation; these may decrease over time.,Avoid alcohol and high-fat meals as they may increase gastrointestinal side effects.,Report symptoms of thyroid tumors: lump in neck, difficulty swallowing, hoarseness.,If severely vomiting or unable to eat/drink, seek medical attention to prevent dehydration and kidney injury.,Do not share pens; store in refrigerator between 36-46°F (2-8°C); protect from light.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENSKYCE vs ALTAVERA, answered by our medical review team.
ENSKYCE is a Oral Contraceptive that works by ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENSKYCE and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENSKYCE is: 2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENSKYCE and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENSKYCE is classified as Category C. No human data available; animal studies show no teratogenic effects at clinically relevant doses. Risk cannot be excluded in first trimester; avoid use unless benefit outweighs ris. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.